Literature DB >> 11786173

DRG-related prices applied in a public health care system--can Finland learn from Norway and Sweden?

Hennamari Mikkola1, Ilmo Keskimäki, Unto Häkkinen.   

Abstract

In the early 1990s, DRG based hospital financing was introduced into some hospital districts in Finland. The 1993 state subsidy reform decentralising all hospital financing to municipalities, and the aim of improving productivity, were the driving forces for introducing DRG. This study addresses the pros and cons of DRG in hospital financing in the Finnish health care system and puts forward several solutions to avoid potential problems. We consider the objectives and optimal features of hospital financing systems in the context of the public health care system, where the public sector owns and finances hospitals. We analyse impacts of introducing different types of DRG based hospital financing systems, taking into account earlier experiences in countries such as Sweden and Norway, as well as Finnish system specific features. DRG could assist the Finnish municipalities to compare quality, costs and prices of services between hospitals, and related cost information might help them budget expenditure more accurately. System specific features mean that traditional uses of DRG in hospital pricing are not feasible in Finland. But some benefits of DRG could be exploited, for instance in the controlled contracts between municipalities and hospitals.

Mesh:

Year:  2002        PMID: 11786173     DOI: 10.1016/s0168-8510(01)00169-5

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  12 in total

1.  Comparing the financial risk of bed-day and DRG based pricing types using parametric and simulation methods.

Authors:  Hennamari Mikkola; Reijo Sund; Miika Linna; Unto Häkkinen
Journal:  Health Care Manag Sci       Date:  2003-05

2.  Will paying the piper change the tune?

Authors:  Jason M Sutherland; Morris L Barer; Robert G Evans; R Trafford Crump
Journal:  Healthc Policy       Date:  2011-05

3.  The possible impact of the German DRGs reimbursement system on end-of-life decision making in a surgical intensive care unit.

Authors:  Peter Stachura; Peter Oberender; Anika C Bundscherer; Christoph H R Wiese
Journal:  Wien Klin Wochenschr       Date:  2015-01-27       Impact factor: 1.704

4.  New casemix classification as an alternative method for budget allocation in thai oral healthcare service: a pilot study.

Authors:  Thunthita Wisaijohn; Atiphan Pimkhaokham; Phenkhae Lapying; Chumpot Itthichaisri; Supasit Pannarunothai; Isao Igarashi; Koichi Kawabuchi
Journal:  Int J Dent       Date:  2010-09-20

5.  Understanding multinational companies in public health systems, using a competitive advantage framework.

Authors:  Jane Lethbridge
Journal:  Global Health       Date:  2011-07-01       Impact factor: 4.185

6.  Review of Diagnosis-Related Group-Based Financing of Hospital Care.

Authors:  Natasa Mihailovic; Sanja Kocic; Mihajlo Jakovljevic
Journal:  Health Serv Res Manag Epidemiol       Date:  2016-05-12

7.  Charting a path forward: policy analysis of China's evolved DRG-based hospital payment system.

Authors:  Rui Liu; Jianwei Shi; Beilei Yang; Chunlin Jin; Pengfei Sun; Lingfang Wu; Dehua Yu; Linping Xiong; Zhaoxin Wang
Journal:  Int Health       Date:  2017-09-01       Impact factor: 2.473

8.  Impacts of Hospital Payment Based on Diagnosis Related Groups (DRGs) with Global Budget on Resource Use and Quality of Care: A Case Study in China.

Authors:  Suwei Yuan; Wenwei Liu; Fengqing Wei; Haichen Zhang; Suping Wang; Weijun Zhu; Jin Ma
Journal:  Iran J Public Health       Date:  2019-02       Impact factor: 1.429

9.  Has payment by results affected the way that English hospitals provide care? Difference-in-differences analysis.

Authors:  Shelley Farrar; Deokhee Yi; Matt Sutton; Martin Chalkley; Jon Sussex; Anthony Scott
Journal:  BMJ       Date:  2009-08-27

10.  Diagnosis-Related Groups' Payment Reform in Beijing.

Authors:  Wei-Ping Jiao
Journal:  Chin Med J (Engl)       Date:  2018-07-20       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.